Sección de Biotecnología, Instituto de Salud Pública de Chile, Chile; Millenium Institute on Immunology and Immunotherapy, Departamento de Genética Molecular y Microbiología, Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile, Santiago, Chile.
Sección de Biotecnología, Instituto de Salud Pública de Chile, Chile.
Mol Immunol. 2018 Nov;103:63-70. doi: 10.1016/j.molimm.2018.08.028. Epub 2018 Sep 8.
The Surface Immunogenic Protein (SIP) of Group B Streptococcus (GBS) had been described as a good target for vaccine development. To date, SIP has been reported as a highly conserved protein, and in a mouse model it induces protection against lethal GBS challenge. Also, similar effects have been described by intranasal immunization with a SIP-based vaccine. In this study, we show the immune response induced by an oral SIP-based vaccine formulated on alum in a mouse model. Our vaccine can reduce vaginal GBS colonization and induce specific SIP-antibodies with opsonophagocytosis activities against GBS. Moreover, we observed the activation of T-cells producing IFN-γ, TNF-α, IL-10, IL-2, and increased expression of the transcription factor T-bet, suggesting a Th1-type humoral response. The oral SIP-based vaccine is a novel alternative in the development of a vaccine against GBS.
B 群链球菌（GBS）的表面免疫蛋白（SIP）已被描述为疫苗开发的一个很好的靶点。迄今为止，SIP 已被报道为一种高度保守的蛋白质，在小鼠模型中，它能诱导针对致死性 GBS 挑战的保护。此外，通过鼻腔内免疫 SIP 为基础的疫苗也描述了类似的效果。在这项研究中，我们展示了一种基于 SIP 的口服疫苗在小鼠模型中用明矾配制所引起的免疫反应。我们的疫苗可以减少阴道 GBS 定植，并诱导具有针对 GBS 的调理吞噬作用的特异性 SIP 抗体。此外，我们观察到产生 IFN-γ、TNF-α、IL-10、IL-2 的 T 细胞的激活，并增加转录因子 T-bet 的表达，提示 Th1 型体液反应。基于 SIP 的口服疫苗是开发 GBS 疫苗的一种新的选择。
